Cerebrospinal Fluid Aβ42/Aβ40 as a Means to Limiting Tube- and Storage-Dependent Pre-Analytical Variability in Clinical Setting.
Fiche publication
Date publication
janvier 2017
Journal
Journal of Alzheimer's disease : JAD
Auteurs
Membres identifiés du Cancéropôle Est :
Pr ALBUISSON Eliane
Tous les auteurs :
Gervaise-Henry C, Watfa G, Albuisson E, Kolodziej A, Dousset B, Olivier JL, Jonveaux TR, Malaplate-Armand C
Lien Pubmed
Résumé
Alzheimer's disease (AD) cerebrospinal fluid (CSF) biomarkers have recently been included in the criteria for AD diagnosis. Unfortunately, their wider use in routine and interpretation require more standardization, particularly for the pre-analytical steps. In particular, amyloid-β (Aβ)42 peptide measurement is strongly influenced by the type of collection tube and by repeated freeze/thaw cycles.
Référence
J. Alzheimers Dis.. 2017 ;57(2):437-445